What is happening
Bone is living tissue that is constantly torn down and rebuilt. Cells called osteoclasts remove old bone; osteoblasts lay down new bone. Through your thirties and forties the two roughly balance.
Estrogen is one of the main brakes on the tearing-down side. When it falls at menopause, resorption accelerates while formation does not keep pace. The result is a period of rapid loss — steepest in the year before the final period and the two years after — during which many women lose a meaningful percentage of their bone density. After that the loss continues, but more slowly.
What is lost is not just density. The internal architecture of trabecular bone thins and connections are lost, which weakens bone more than a density number alone suggests.
Why this belongs in a menopause visit
Bone loss is silent. There is no ache that tells you it is happening. The first sign, for too many women, is a broken wrist, a compressed vertebra, or a hip fracture — and a hip fracture after 65 carries serious consequences for independence and survival.
Meanwhile there is a well-defined window, right around menopause, where treatment decisions are most consequential and where a woman is likely to be in front of a clinician for another reason. Treating hot flashes and ignoring bone is a missed opportunity. So we ask about bone at every menopause visit, calculate risk when it is relevant, and order the scan when it is due.
How we approach it
We start with history: any fracture as an adult, when your periods stopped, steroid use, rheumatoid arthritis, family history of hip fracture, smoking, alcohol, weight, and medications that affect bone. We measure your height and compare it to your tallest adult height.
If you are due for screening, we order a DEXA, and where it is indicated we add vertebral fracture assessment — a low-dose image of the spine taken on the same machine — because silent vertebral fractures are common and change treatment.
We then calculate FRAX and put the numbers together. If you need treatment, we go through the options: bisphosphonates, denosumab including biosimilars, romosozumab, and teriparatide, plus hormone therapy where it fits. Each has a different profile, a different route, a different duration, and a different plan for what happens when you stop — which matters more than most people are told.
Then we set a follow-up interval and stick to it.